BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32532461)

  • 1. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection.
    Callejas Rubio JL; Luna Del Castillo JD; de la Hera Fernández J; Guirao Arrabal E; Colmenero Ruiz M; Ortego Centeno N
    Med Clin (Barc); 2020 Aug; 155(4):159-161. PubMed ID: 32532461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection.
    Callejas Rubio JL; Luna Del Castillo JD; de la Hera Fernández J; Guirao Arrabal E; Colmenero Ruiz M; Ortego Centeno N
    Med Clin (Engl Ed); 2020 Aug; 155(4):159-161. PubMed ID: 32835105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evolution and treatment of storm cytoquine syndrome associated to SARS-CoV-2 infection among octogenarians].
    Callejas Rubio JL; Aomar Millán I; Moreno Higueras M; Muñoz Medina L; López López M; Ceballos Torres Á
    Rev Esp Geriatr Gerontol; 2020; 55(5):286-288. PubMed ID: 32564984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
    Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
    Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
    Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
    Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
    Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
    Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.
    Gautier-Vargas G; Baldacini C; Benotmane I; Keller N; Perrin P; Moulin B; Caillard S
    Kidney Int; 2020 Aug; 98(2):508-509. PubMed ID: 32505467
    [No Abstract]   [Full Text] [Related]  

  • 10. Tocilizumab for severe COVID-19: a systematic review and meta-analysis.
    Lan SH; Lai CC; Huang HT; Chang SP; Lu LC; Hsueh PR
    Int J Antimicrob Agents; 2020 Sep; 56(3):106103. PubMed ID: 32712333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
    Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
    J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab administration in a refractory case of COVID-19.
    Dastan F; Nadji SA; Saffaei A; Tabarsi P
    Int J Antimicrob Agents; 2020 Aug; 56(2):106043. PubMed ID: 32502524
    [No Abstract]   [Full Text] [Related]  

  • 14. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
    Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
    Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
    [No Abstract]   [Full Text] [Related]  

  • 15. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.
    Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA
    Int Immunopharmacol; 2020 Nov; 88():106926. PubMed ID: 32889236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
    Ranger A; Haji R; Kaczmarski R; Danga A
    Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan.
    Tu WJ; Cao J; Yu L; Hu X; Liu Q
    Intensive Care Med; 2020 Jun; 46(6):1117-1120. PubMed ID: 32253448
    [No Abstract]   [Full Text] [Related]  

  • 18. Early tocilizumab treatment could improve survival among COVID-19 patients.
    Campins L; Boixeda R; Perez-Cordon L; Aranega R; Lopera C; Force L
    Clin Exp Rheumatol; 2020; 38(3):578. PubMed ID: 32456769
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 and Hypercoagulability.
    Sholzberg M
    Clin Adv Hematol Oncol; 2020 Jul; 18(7):386-389. PubMed ID: 32903249
    [No Abstract]   [Full Text] [Related]  

  • 20. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.
    Faguer S; Del Bello A; Abravanel F; Nicolau-Travers ML; Kamar N
    Ann Intern Med; 2020 Sep; 173(6):501-503. PubMed ID: 32432518
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.